A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Primary Objective

To assess the safety and tolerability of INCB057643 as monotherapy and in combination with ruxolitinib

Is This Study For You?

Let's Get Started!




CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Brandon McMahon

Brandon McMahon

Study ID

Protocol Number: 22-0130

More information available at ClinicalTrials.gov: NCT04279847


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers